| Acronyme | Sponsor/Promoteur | Titre du projet | Lien vers CT |
| ADRENOSS II | ADRENOMED | Treatment of Patients With Early Septic Shock and Bio-Adrenomedullin(ADM) Concentration > 70 pg/ml With ADRECIZUMAB | NCT03085758 |
| ART123 | ASAHI KASEI PHARMA | Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy | NCT01598831 |
| CALO2-001 | COMBIOXIN SA | Safety, Tolerability, Efficacy and Pharmacodynamics of CAL02 in Severe Pneumonia Caused by Streptococcus Pneumoniae | NCT02583373 |
| CAPE-COD | CHU Tours | Community-Acquired Pneumonia : Evaluation of Corticosteroids | NCT02517489 |
| COMBACTE - EVADE | IMI - MedImmune | Effort to Prevent Nosocomial Pneumonia Caused by Pseudomonas Aeruginosa in Mechanically Ventilated Subjects | NCT02696902 |
| COMBACTE - SAATELLITE | IMI - MedImmune | Study of the Efficacy and Safety of MEDI4893 | NCT02296320 |
| MOT-C-201 | INOTREM | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 3 Doses of MOTREM in Patients With Septic Shock | NCT03158948 |
| SEPCELL | TIGENIX | Cx611-0204 SEPCELL Study | NCT03158727 |
| SPRINT SARI | Australian and New Zealand Intensive Care Research Centre | Short PeRiod IncideNce sTudy of Severe Acute Respiratory Infection | NCT02498587 |
| THANE | Assistance Publique - Hôpitaux de Paris | Pilot Phase II Study: Hemodynamic Tolerance and Anti-inflammatory Effects of Esmolol During the Treatment of Septic Shock | NCT02120404 |
| TRIAGE | BIOMERIEUX | TRIAGE: TRIage of Sepsis At emerGency dEpartment | NCT02739152 |